EcoDrugPlus

Glucokinase

Ensembl ID : ENSPMRG00000017579
Gene Symbol: GCK
3 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSPMRG00000007592
Gene Symbol: GRIA1
3 Cross references
323 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSPMRG00000012218
Gene Symbol: GRIA2
3 Cross references
321 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Ampa Type Subunit 3

Ensembl ID : ENSPMRG00000019489
Gene Symbol: GRIA3
3 Cross references
318 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Ampa Type Subunit 4

Ensembl ID : ENSPMRG00000010863
Gene Symbol: GRIA4
3 Cross references
324 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Nmda Type Subunit 1

Ensembl ID : ENSPMRG00000009954
Gene Symbol: GRIN1
2 Cross references
278 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSPMRG00000013094
Gene Symbol: GRIN2A
1 Cross references
227 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSPMRG00000019789
Gene Symbol: GRIN2B
3 Cross references
330 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSPMRG00000013920
Gene Symbol: GRIN2C
3 Cross references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Nmda Type Subunit 2d

Ensembl ID : ENSPMRG00000020842
Gene Symbol: GRIN2D
1 Cross references
278 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Nmda Type Subunit 3b

Ensembl ID : ENSPMRG00000020765
Gene Symbol: GRIN3B
1 Cross references
286 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSPMRG00000003621
Gene Symbol: GRIK1
1 Cross references
302 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).